Barclays Upgrades Elanco Animal Health (NYSE:ELAN) to “Strong-Buy”

Elanco Animal Health (NYSE:ELAN) was upgraded by equities research analysts at Barclays to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other equities analysts also recently issued research reports about the company. UBS Group boosted their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. KeyCorp started coverage on shares of Elanco Animal Health in a research note on Friday, November 21st. They set an “overweight” rating and a $27.00 price objective for the company. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Wednesday, November 19th. Finally, Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.78.

Elanco Animal Health Stock Performance

NYSE:ELAN traded up $0.38 during trading hours on Monday, reaching $20.81. The company had a trading volume of 581,056 shares, compared to its average volume of 5,840,007. The firm has a market cap of $10.34 billion, a price-to-earnings ratio of 346.91, a PEG ratio of 2.94 and a beta of 1.86. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm’s 50 day moving average price is $21.69 and its 200-day moving average price is $17.93. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $23.70.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. SJS Investment Consulting Inc. raised its holdings in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares in the last quarter. Huntington National Bank raised its holdings in shares of Elanco Animal Health by 136.7% in the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after purchasing an additional 1,087 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after purchasing an additional 951 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after purchasing an additional 2,807 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.